26 Stocks Moving in Monday’s Pre-Market Session
Gainers
ERYTECH Pharma S.A. (NASDAQ: ERYP) shares rose 88.4% to $2.30 in pre-market trading. Erytech Pharma recently announced publication of results from Eryapasse Phase 2 trial as treatment for hypersensitive ALL in the British Journal of Haematology.
22 Stocks Moving in Friday’s Pre-Market Session
Gainers
Moving iMage Technologies, Inc. (NASDAQ: MITQ) rose 41.7% to $1.63 in pre-market trading. Moving iMage Technologies and SNDBX reported a strategic partnership for gaming and e-Sports.
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers
Hoth Therapeutics (NASDAQ:HOTH) stock rose 156.5% to $1.58 during Monday's pre-market session. The market value of their outstanding shares is at $37.8 million.
Genocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor Patients
Genocea Biosciences Inc (NASDAQ: GNCA) has
Genocea Presents Initial Data From GEN-011 Phase 1/2a Trial At AACR 2022 Annual Meeting
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, presents clinical, preclinical, and manufacturing data at the American Association
Genocea Biosciences Earnings Preview
Genocea Biosciences (NASDAQ:GNCA) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement.
Analysts estimate that Genocea Biosciences will report an earnings per share (EPS) of $-0.20.
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.
Genocea Biosciences Enters R&D Collaboration And Option Agreement With Janssen
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, has entered into an R&D collaboration and option agreement with Janssen Biotech, Inc.,